Close mobile menu×
Close mobile menu

Selim M. Arcasoy, MD

Board Certifications: 
Critical Care Medicine, Internal Medicine, Pulmonary Disease, Pulmonary Disease, Critical Care Medicine
Expertise in: 
Pediatric Pulmonology
Accepting New Patients
Treats Children
Profile Hero

Schedule an Appointment

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Credentials & Experience

America's Top Doctor
NY Top Doctor

Board Certifications

  • Critical Care Medicine
  • Internal Medicine
  • Pulmonary Disease
  • Pulmonary Disease
  • Critical Care Medicine

Clinical Expertise

  • Critical Care Medicine
  • Internal Medicine
  • Lung Transplant
  • Pediatric Pulmonology
  • Transplant Pulmonology

Education & Training

  • Ege University Medical School, Turkey
  • 1990 Ege University School of Medicine
  • Internship: 1993 State University of New York Health Science Center at Brooklyn
  • Residency: 1993 State University Of New York Downstate Medical Cen
  • Residency: 1994 State University of New York Health Science Center at Brooklyn
  • Fellowship: 1997 The University of Pittsburgh Medical Center
  • Fellowship: 1997 University Of Pittsburgh Medical Center

Honors & Awards

2016- Fellow of the American Society of Transplantation (F.A.S.T.)

2002-17- Inclusion in America’s Top Doctors and Top Doctors: New York Metro Area

2009-18- Inclusion in New York City Super Doctors, New York Times Magazine

2002- Fellow of the American College of Physicians (F.A.C.P.)

2001- Fellow of the American College of Chest Physicians (F.C.C.P.)

1990- Rank Valedictorian of class in Ege University School of Medicine

1984- Rank Valedictorian of class in Tarsus American College

About Selim Arcasoy

selim_arcasoy_md

Dr. Arcasoy was recruited to Columbia University/NewYork-Presbyterian Hospital as the Medical Program Director of Lung Transplantation in 2001 from the University of Pennsylvania, where he was a key member of the Advanced Lung Disease and Lung Transplantation Program in the Division of Pulmonary and Critical Care Medicine. After his recruitment, he completely turned around the Lung Transplantation Program to rank amongst the top 5 to 10 programs in the country with regards to volume and top 1 to 3 programs in terms of patient survival. Under his leadership, the Lung Transplant Program has performed 60-70 transplants annually in the past 6 years with a record number of 71 transplants in 2017. Despite high transplant volumes and very sick pretransplant candidates, the survival of lung transplant recipients has remained significantly above the national average. Currently, 1-year survival of lung transplant recipients at Columbia University is 90%, 5-year survival 68%, and 10-year survival 46% (as compared to 85%, 55%, and 28% national average survival at the same time points).

Dr. Arcasoy has gained national and international reputation with various leadership roles in many professional organizations and scientific societies. He previously chaired the Thoracic Organ Transplant Committee of the American Society of Transplantation and the Transplant Network Steering Committee of the American College of Chest Physicians. Dr. Arcasoy is a Fellow of the American College of Physicians (FACP), American College of Chest Physicians (FCCP), and American Society of Transplantation (FAST). He serves as a reviewer for many scientific journals. Dr. Arcasoy has been named in America's Top Doctors and Top Doctors: New York Metro area in the past 16 consecutive years. He has also been selected in the New York Times Super Doctors list in the past 10 years.

Dr. Arcasoy's main research interests include outcomes of patients with advanced lung disease before and after lung transplantation, post-transplant complications, optimization of post-transplant immunosuppression via multicenter clinical trials and collaborative investigation in immune tolerance, studies of genetic testing for diagnosis of organ rejection, various post-transplant complications and lung allocation policy. His research has been published in journals such as the New England Journal of Medicine, American Journal of Respiratory and Critical Care Medicine, Annals of Internal Medicine, Chest, American Journal of Transplantation, Journal of Heart and Lung Transplantation, Gene Therapy, and Transplantation. Between 2011 and 2013, Dr. Arcasoy attended the Executive Program and obtained his Master of Public Health degree in Healthcare Policy and Management from Columbia University Mailman School of Public Health. He maintains a very busy clinical practice in addition to administration of the Lung Transplant Program, teaching and clinical research. He is also heavily engaged in philanthropy and works arm in arm with some of his grateful patients to raise funds to meet the needs of his Program and patients focusing on cutting-edge research, education and building a strong patient community.

Academic Titles

  • Dickinson W. Richards, Jr. Professor of Medicine (in Pediatrics) at CUMC

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center
  • NewYork-Presbyterian Morgan Stanley Children's Hospital

Languages

  • Turkish

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs Plan

Amida Care

  • Special Needs Plan

Capital District Physician Health Plan

  • Capital District Physician Health Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs Plan

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

Research

Advanced lung disease and lung transplantation

Research Interests

  • Co-morbidities in advanced pulmonary disease
  • Idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis
  • Lung volume reduction for emphysema
  • Novel immunosuppressive regimens and antimicrobial therapies in lung transplantation
  • Patient selection and outcomes on the waiting list for lung transplantation
  • Predictors and diagnosis of acute and chronic lung rejection
  • Pulmonary embolism and thrombolytic therapy

Grants

A PHASE 3 MULTICENTER OPEN LABEL EXTENSION CLINICAL TRIAL TO DEMONSTRATE THE EFFECTIVENESS AND SAFETY OF LIPOSOMAL CYCLOSPORINE A INHALATION SOLUTION DELIVERED VIA THE PARI INVESTIGATIONAL EFLOW DEVICE PLUS STANDARD OF CARE IN THE TREATMENT OF BRONCHIOLI (P&S Industry Clinical Trial)

Jun 15 2020 - Jun 15 2025

PHASEIII, PROSPECTIVE, MULTICENTER, RANDOMIZED, CONTROLLED CLINICAL TRIAL TO DEMONSTRATE THE EFFECTIVENESS AND SAFETY OF LIPOSOMAL CYCLOSPORINE A (L-CSA) INHALATION. SOLUTION DELIVERED VIA THE PARI INVESTIGATIONAL EFLOW? DEVICE PLUS STANDARD (P&S Industry Clinical Trial)

Aug 28 2019 - Aug 28 2024

APHASE III, PROSPECTIVE, MULTICENTER, RANDOMIZED, CONTROLLED CLINICAL TRIAL TO DEMONSTRATE THE EFFECTIVENESS AND SAFETY OF LIPOSOMAL CYCLOSPORINE A (L-CSA) INHALATION. SOLUTION DELIVERED VIA THE PARI INVESTIGATIONAL EFLOW? DEVICE PLUS STANDARD (P&S Industry Clinical Trial)

Aug 28 2019 - Aug 28 2024

CF LUNG TRANSPLANT TRANSITION LEARNING AND LEADERSHIP COLLABORATIVE 2 (Private)

May 1 2019 - Jun 30 2020

ALNYLAM ALN-RSVP1-09 (P&S Industry Clinical Trial)

Jun 22 2010 - Jun 22 2015

ANOPEN-LABEL,MULTICENTER,EXTENSION STUDY OF CYCLOSPORINE INHALATION SOLUTION IN SUBJECTS PREVIOUSLY ENROLLED IN THE APT (P&S Industry Clinical Trial)

Oct 28 2009 - Oct 28 2014

INHALED CYCLOSPORINE (P&S Industry Clinical Trial)

Nov 25 2008 - May 31 2013

IVIG FOR ACQUIRED IMMUNODEFICIENCY IN LUNG TRANSPLANT PATIENTS (P&S Industry Clinical Trial)

Mar 31 2005 - Dec 31 2010

Selected Publications

L.J. Benvenuto, D.R. Anderson, H.P. Kim, J.L. Hook, L. Shah, H.Y. Robbins, F. D'Ovidio, M. Bacchetta, J.R. Sonett, S.M. Arcasoy. Geographic disparities in donor lung supply and lung transplant waitlist outcomes: A Cohort Study. Am J Transplant; 2017: DOI: 10.1111/ajt.14630.

A.M. Layton, H.F. Armstrong, H.P. Kim, K.S. Meza, F. D'Ovidio, S.M. Arcasoy. Cardiopulmonary exercise factors predict survival in patients with advanced interstitial lung disease referred for lung transplantation. Respir Med 2017; 126: 59-67

J. Costa, S. Sreekanth, A. Kossar, K. Raza, H. Robbins, L. Shah, J.R. Sonett, S. Arcasoy, F. D'Ovidio. Donors with a prior history of cardiac surgery are a viable source of lung allografts. Eur J Cardiothorac Surg 2016;50:822-25.

J. Costa, S. Sreekanth, A. Kossar, K. Raza, D.J. Lederer, H. Robbins, L. Shah, J.R. Sonett, S. Arcasoy, F. D'Ovidio. Donor lung assessment using selective pulmonary vein gases. Eur J Cardiothorac Surg 2016;50:826-31.

JL Sell, M Bacchetta, SB Goldfarb, H Park, PV Heffernan, HA Robbins, L Shah, K Raza, F D'Ovidio, JR Sonett, SM Arcasoy, DJ Lederer. Short Stature and Access to Lung Transplantation in the United States. A Cohort Study. Am J Respir Crit Care Med 2016;193(6):681-8.